A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.

• Status: Completed
• Trial end date: 2004-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the efficacy of a 12-week treatment with darifenacin in increasing warning time, the time from first sensation of urgency to voiding, in patients with OAB.

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Darifenacin

Criteria

Inclusion Criteria:

• Three symptoms of OAB (urge incontinence, frequency and urgency) for at least six months prior to Visit 2.

• Patients capable of independent toileting and able of independently completing the patient diary.

Exclusion Criteria:

• Patients in whom the use of anticholinergic drugs was contraindicated

• Evidence of severe liver disease

• Patients with other clinically significant urinary or gynecological conditions

Other protocol-defined inclusion/exclusion criteria may apply.